Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up
Oncology
[키워드] accumulate
acute respiratory syndrome
antiviral therapy
B cell
B cells
B-cell
Blood
Cell
chronic lymphocytic leukemia
circulating
clearance
Clinical characteristics
CLL
CLL patients
clone
Cluster
combination regimen
coronavirus
coronavirus disease-2019
COVID
COVID-19
criteria
cytoplasm
deficiency
demonstrated
diagnosed with COVID-19
distribution
early stage
effective
etiology
female
flow cytometry
Follow-up
help
Hematological malignancy
High-dose
highest
home quarantine
hospital
human-to-human transmission
humoral immune response
Humoral immunity
IgG antibody
IgM and IgG
immune
Ineffective
ineffective clearance
infected with COVID-19
Infection
Intravenous immunoglobulin
Isolation
laboratory result
leukemia
Lung injury
lymphocyte
lymphocytosis
outbreak
Patient
plasma
prevent disease progression
progeny
progression
reported
response
severe disease
severe pneumonia
suffered
T lymphocytes
therapy
Viral load
virus infection
Wuhan, China
[DOI] 10.3389/fonc.2020.01272 PMC 바로가기 [Article Type] Oncology
[DOI] 10.3389/fonc.2020.01272 PMC 바로가기 [Article Type] Oncology